SCHEMBL3810280

SCHEMBL3810280

CC(C)(C)OC(=O)CN(CCCCCCN)Cc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 9/20 0.47
CHRM2 P08172 3/20 0.47
CHRM4 P08173 2/20 0.47
CHRM5 P08912 2/20 0.47
CHRM1 P11229 2/20 0.47
CHRM3 P20309 2/20 0.47
HRH1 P35367 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LIN28A Q9H9Z2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TERT O14746 1/20 0.37
CYP1A2 P05177 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469931 0.88 SMN1; SMN2 (0.42) MAPTSMN1; SMN2LIN28ATDP1TERT
SCHEMBL13388472 0.87 SMN1; SMN2 (0.46) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL19889254 0.87 MAPT (0.58) MAPTSMN1; SMN2LIN28ATDP1TERT
SCHEMBL3927566 0.85 CXCR4 (0.47) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2476921 0.85 CYP3A4 (0.42) CXCR4MAPTSMN1; SMN2LIN28ATDP1
SCHEMBL2474014 0.84 SLC1A5 (0.48) MAPTSMN1; SMN2LIN28ATDP1CYP1A2
SCHEMBL2474008 0.84 SLC1A5 (0.48) MAPTSMN1; SMN2LIN28ATDP1CYP1A2
SCHEMBL3928577 0.84 CXCR4 (0.47) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL15834891 0.83 MAPT (0.39) MAPTSMN1; SMN2LIN28ATDP1TERT
SCHEMBL20506840 0.83 MAPT (0.49) MAPTSMN1; SMN2LIN28ATDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090180951-A1 INHIBITORS OF INTEGRIN VLA-4 MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-20090180951-A1 INHIBITORS OF INTEGRIN VLA-4 MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-07-16 US disclosed
WO-2009076434-A1 INHIBITORS OF INTEGRIN VLA-4 MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090180951-A1 INHIBITORS OF INTEGRIN VLA-4 ITGA1, ITGB1, ITGA4 CXCR4 142/4885CHRM2 496/4885CHRM4 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.